Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure
Por:
Aimo, A, Vergaro, G, Ripoli, A, Bayes-Genis, A, Figal, DAP, de Boer, RA, Lassus, J, Mebazaa, A, Gayat, E, Breidthardt, T, Sabti, Z, Mueller, C, Brunner-La Rocca, HP, Tang, WHW, Grodin, JL, Zhang, YH, Bettencourt, P, Maisel, AS, Passino, C, Januzzi, JL and Emdin, M
Publicada:
1 abr 2017
Categoría:
Cardiology and cardiovascular medicine
Resumen:
OBJECTIVES The aim of this study was to perform a meta-analysis of currently available data regarding the prognostic significance of soluble suppression of tumorigenecity-2 (sST2) concentration in acute heart failure (AHF).
BACKGROUND Concentration of sST2 may have prognostic value in AHF. A comprehensive assessment of all available studies regarding sST2 in AHF is lacking.
METHODS Three databases (MEDLINE, Cochrane Library, and Scopus) were searched. Inclusion criteria were follow-up studies, papers published in English, enrollment of patients with AHF, and availability of median hazard ratios for all-cause death and other outcome measures, when available.
RESULTS Ten studies were included, with a global population of 4,835 patients and a median follow-up duration of 13.5 months. The following global hazard ratios calculated for log(2)(sST2) were admission sST2 and all-cause death, 2.46 (95% confidence interval [CI]: 1.80 to 3.37; p < 0.001); discharge sST2 and all-cause death, 2.06 (95% CI: 1.37 to 3.11; p < 0.001); admission sST2 and cardiovascular death, 2.29 (95% CI: 1.41 to 3.73; p < 0.001); discharge sST2 and cardiovascular death, 2.20 (95% CI: 1.48 to 3.25; p < 0.001); admission sST2 and heart failure (HF) hospitalization, 1.21 (95% CI: 0.96 to 1.52; p = 0.060); discharge sST2 and HF hospitalization, 1.54 (95% CI: 1.03 to 2.32; p = 0.007); admission sST2 and all-cause death or HF hospitalization, 1.74 (95% CI: 1.24 to 2.45; p < 0.001); and discharge sST2 and all-cause death or HF hospitalization, 1.63 (95% CI: 1.14 to 2.33; p < 0.001).
CONCLUSIONS Plasma sST2 has prognostic value with respect to all-cause and cardiovascular death as well as the composite outcome of all-cause death or HF hospitalization, with both admission and discharge values having prognostic efficacy. Discharge sST2, but not admission sST2, is predictive of HF rehospitalization during follow-up. (C) 2017 by the American College of Cardiology Foundation.
Filiaciones:
Aimo, A:
Scuola Super Sant Anna, Pisa, Italy
Vergaro, G:
Scuola Super Sant Anna, Pisa, Italy
Fdn Toscana G Monasterio, Pisa, Italy
Ripoli, A:
Fdn Toscana G Monasterio, Pisa, Italy
:
Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
Figal, DAP:
Univ Murcia, Hosp Univ Arrixaca, Murcia, Spain
de Boer, RA:
Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
Lassus, J:
Helsinki Univ Hosp, Heart & Lung Ctr, Helsinki, Finland
Mebazaa, A:
Univ Helsinki, Helsinki, Finland
Univ Paris Diderot, Hop Univ St Louis Lariboisiere, AP HP, INSERM U 942, Paris, France
Breidthardt, T:
Univ Basel, Basel, Switzerland
Sabti, Z:
Univ Basel, Basel, Switzerland
Mueller, C:
Univ Basel, Basel, Switzerland
Brunner-La Rocca, HP:
Maastricht Univ, Med Ctr, Dept Cardiol, Maastricht, Netherlands
Tang, WHW:
Cleveland Clin, Inst Heart & Vasc, Cleveland, OH USA
Grodin, JL:
Univ Texas Southwestern Med Ctr Dallas, Div Cardiol, Dept Internal Med, Dallas, TX USA
Zhang, YH:
Peking Union Med Coll, Beijing, Peoples R China
Bettencourt, P:
Univ Porto, Sch Med, Oporto, Portugal
Maisel, AS:
Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
Januzzi, JL:
Massachusetts Gen Hosp, Boston, MA 02114 USA
Harvard Clin Res Inst, Boston, MA USA
Emdin, M:
Fdn Toscana G Monasterio, Pisa, Italy
Bronze, Green Published
|